Forskergruppen bidrar med klinisk forskning for å forbedre behandlingsresultater for pasienter med kolorektal kreft og analkreft.

Medlemmer av forskergruppen er aktive i ulike studier ved utprøvende medikamentell behandling, strålebehandling, multidisiplinær behandling, translasjonsforskning, og prosjekter innen epidemiologi, seneffekter og livskvalitet. Det er utstrakt multidisiplinært, nasjonalt, nordisk og internasjonalt samarbeid om flere prosjekter.

Kliniske studier

  • Ny medikamentell kreftbehandling
  • Strålebehandling
  • Multimodal kreftbehandling

Forskergruppen deltar i studier av ny medikamentell kreftbehandling. Gruppen har deltatt i flere studier som har endret klinisk praksis, med målrettet medikamentell behandling, immun sjekkpunkt hemming, eller optimal kombinasjon av multimodal behandling.

Epidemiologisk forskning

  • Tykk- og endetarmskreft; insidens, overlevelse, og oligometastatisk sykdom (PhD prosjekt)
  • Livskvalitet etter behandling for tykk- og endetarmskreft
  • Overlevelse av tykk- og endetarmskreft

Forskergruppen har flere samarbeidsprosjekter med forskere i Kreftregisteret.

Translasjonsforskning

  • BIOMAN
  • ctDNA

Forskergruppen har langvarig samarbeid med Avdeling for molekylær onkologi, Institutt for kreftforskning, og nordiske samarbeidsprosjekter om ctDNA.

Disputaser siden 2020

• Kathinka Schmidt Slørdahl. “Treatment outcomes after chemoradiotherapy for anal cancer and patient reported outcomes after treatment for anorectal cancer in Norway”. UiO, 18.12.25.

• Julian Hamfjord. “Colorectal cancer - survival trends and prognostic role of circulating cell-free DNA”. UiO, 16.2.24.

• Tor Magnus Smedman. “Liver transplantation for non-resectable liver metastases – health-related quality of life, treatment after recurrence, and survival outcomes”. UiO, 19.6.23.

• Elin Aamdal. “Treating metastatic melanoma with ipilimumab – Clinical activity, health-related quality of life and combination with a telomerase peptide vaccine”. UiO, 22.6.22.

• Jørgen Smeby. “Molecular subtype-dependent impact of driver mutations in colorectal cancer”. UiO, 20.4.2020.

• Kari Röhrl. “Symptoms and quality of life during chemotherapy in patients with colorectal cancer”. UiO, 13.3.2020.

Utvalgte publikasjoner

Ystgaard MF, Myklebust TÅ, Smeby J, Larsen IK, Guren TK, Kure EH, Tveit KM, Glimelius B, Guren MG, Hamfjord J. Early-onset colorectal cancer incidence in Norway: a national registry based study 1993–2022 by subsite and morphology. ESMO Gastrointestinal Oncology 2025; 7: 100065.

Hofheinz R-D, Fokas E, Benhaim L, Price TJ, Arnold D, Beets-Tan R, Guren MG, Hospers GAP, Lonardi S, Nagtegaal I, Perez R, Cervantes A & Martinelli E, on behalf of the ESMO Guidelines Committee. Localised rectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Annals of Oncology 2025; 36 (9): 1007-24.

Hamfjord J, Myklebust TÅ, Larsen IK, Kure EH, Glimelius B, Guren TK, Tveit KM, Guren MG. Survival trends of right- and left-sided colon cancer across four decades: a Norwegian population-based study. Cancer Epidemiology, Biomarkers & Prevention 2022; 31 (2): 342-51.

Rao S, Guren MG, Khan K, Brown G, Renehan AG, Steigen SE, Deutsch E, Martinelli E, Arnold D, on behalf of the the ESMO Guidelines Committee. Anal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology 2021; 32 (9): 1087-1100.

Tabernero J, Grothey A, Van Cutsem E, Yaeger R, Wasan H, Yoshino T, Desai J, Ciardiello F, Loupakis F, Hong YS, Steeghs N, Guren TK, Arkenau HT, Garcia-Alfonso P, Elez E, Gollerkeri A, Maharry K, Christy-Bittel J, Kopetz S. Encorafenib Plus Cetuximab as a New Standard of Care for Previously Treated BRAF V600E-Mutant Metastatic Colorectal Cancer: Updated Survival Results and Subgroup Analyses from the BEACON Study. Journal of Clinical Oncology 2021; 39 (4): 273-84.

Rao S, Sclafani F, Eng C, Adams RA, Guren MG, Sebag-Montefiore D, Benson A, Bryant A, Peckitt C, Segelov E, Roy A, Seymour MT, Welch J, Saunders MP, Muirhead R, O’Dwyer P, Bridgewater J, Bhide S, Glynne-Jones R, Arnold D, Cunningham D. International Rare Cancers Initiative Multicenter Randomized Phase II Trial of Cisplatin and Paclitaxel in Advanced Anal Cancer: InterAAct. Journal of Clinical Oncology 2020; 38 (22): 2510-18.

Bruun J, Kryeziu K, Eide PW, Moosavi SH, Eilertsen, I, Langerud J, Røsok B, Totland MZ, Brunsell TH, Pellinen T, Saarela J, Bergsland CH, Palmer HG, Brudvik KW, Guren T, Dienstmann R, Guren MG, Nesbakken A, Bjørnbeth BA, Sveen A, Lothe RA. Patient-Derived Organoids from Multiple Colorectal Cancer Liver Metastases Reveal Moderate Intra-patient Pharmacotranscriptomic Heterogeneity. Clinical Cancer Research 2020; 26 (15): 4107-19.

Kopetz S, Grothey A, Yaeger R, Van Cutsem E, Desai J, Yoshino T, Wasan H, Ciardiello F, Loupakis F, Hong YS, Steeghs N, Guren TK, Arkenau HT, Garcia-Alfonso P, Pfeiffer P, Orlov S, Lonardi S, Elez E, Kim TW, Schellens JHM, Guo C, Krishnan A, Dekervel J, Morris V, Calvo Ferrandiz A, Tarpgaard LS, Braun M, Gollerkeri A, Keir C, Maharry K, Pickard M, Christy-Bittel J, Anderson L, Sandor V, Tabernero J. Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-mutated Colorectal Cancer. N Engl J Med 2019; 381 (17): 1632-43.

Guren MG. The global challenge of colorectal cancer. Lancet Gastroenterology and Hepatology 2019; 4 (12): 894-95.

Smeby J, Sveen A, Merok MA, Danielsen SA, Eilertsen IA, Guren MG, Dienstmann R, Nesbakken A, Lothe RA. CMS-dependent prognostic impact of KRAS and BRAF V600E mutations in primary colorectal cancer. Annals of Oncology 2018; 29 (5): 1227-34.